SCHEMBL116883

SCHEMBL116883

Nc1ccc2ncsc2c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 1/20 0.58
NPC1 O15118 7/20 0.52
RAB9A P51151 7/20 0.52
KDM4E B2RXH2 4/20 0.52
HKDC1 Q2TB90 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
ALDH1A1 P00352 3/20 0.50
HSD17B10 Q99714 2/20 0.50
SMN1; SMN2 Q16637 3/20 0.46
PTPN11 Q06124 1/20 0.43
GLA P06280 3/20 0.43
GAA P10253 3/20 0.43
MAPT P10636 3/20 0.43
KEAP1 Q14145 1/20 0.42
VRK1 Q99986 1/20 0.41
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
PKM P14618 2/20 0.41
HPGD P15428 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL8990150 0.98 DYRK1A (0.56) DYRK1ANPC1RAB9AKDM4EHKDC1
SCHEMBL31452850 0.89 DYRK1A (0.49) DYRK1ANPC1RAB9AKDM4EHKDC1
SCHEMBL22130152 0.84 DYRK1A (0.70) DYRK1ANPC1RAB9AKDM4EHKDC1
Trifluoroacetic Acid SCHEMBL5028767 0.83 NPC1 (0.54) DYRK1ANPC1RAB9AKDM4EHKDC1
SCHEMBL27835644 0.83 NPC1 (0.50) DYRK1ANPC1RAB9AKDM4EHKDC1
SCHEMBL29363971 0.83 ALDH1A1 (0.50) DYRK1ANPC1RAB9AKDM4EHKDC1
SCHEMBL115598 0.83 ALDH1A1 (0.50) DYRK1ANPC1RAB9AKDM4EHKDC1
Hydrochloric Acid SCHEMBL16861131 0.81 ALDH1A1 (0.48) DYRK1ANPC1RAB9AKDM4EHKDC1
Methane SCHEMBL11806579 0.81 ALDH1A1 (0.48) DYRK1ANPC1RAB9AKDM4EHKDC1
SCHEMBL15688976 0.79 SMN1; SMN2 (0.43) DYRK1ANPC1RAB9AKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1491 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4720318-A1 METHODS AND COMPOSITIONS FOR THE PRODUCTION OF GLYOXAL Solugen, Inc. (US) 2026-04-08 EP claimed
US-20250178995-A1 COMPOSITIONS AND METHODS FOR THE PRODUCTION OF GLUCARIC ACID SOLUGEN, INC. (US) 2025-06-05 US claimed
CN-119968007-A Perovskite solar cell based on ion-induced interface electric field and preparation method thereof 嘉庚创新实验室 2025-05-09 CN claimed
WO-2025076549-A1 SMALL MOLECULE ACTIVATORS SOLUGEN, INC. (US) 2025-04-10 WO claimed
CN-119241449-A Piperazine derivative and preparation method and application thereof 重庆市畜牧科学院 2025-01-03 CN claimed
CN-119080714-A Azobenzenesulfonate compound, preparation method and application thereof, and preparation method of radioactive probe 四川大学 2024-12-06 CN claimed
WO-2024249896-A1 METHODS AND COMPOSITIONS FOR THE PRODUCTION OF GLYOXAL SOLUGEN, INC. (US) 2024-12-05 WO claimed
CN-115354369-B Ultra-deep hole TSV electroplating solution for MEMS device packaging 珠海市创智成功科技有限公司 2024-11-22 CN claimed
CN-115449860-B Nickel-gold electroplating liquid for ceramic substrate and electroplating process thereof 深圳创智芯联科技股份有限公司 2024-08-20 CN claimed
CN-118290352-A Azo compound, preparation method and application thereof, and medicinal composition 四川大学 2024-07-05 CN claimed
US-6372077-B1 COATING A FIBER WITH A POWDER ENCAPSULANT MATERIAL IN A HIGHLY DISPERSED COLLOIDAL SUSPENSION SUCH THAT THE ENCAPSULATED PARTICLES REMAIN INDEPENDENT AND DISCRETE UPON SEPARATION TECLE BERHAN (US) 2002-04-16 US claimed
EP-0917501-B1 METHOD FOR ISOLATING ULTRAFINE AND FINE PARTICLES AND RESULTING PARTICLES TECLE BERHAN (US) 2001-09-19 EP claimed
EP-1132127-A2 Method for isolating ultrafine and fine particles and resulting particles Tecle, Berhan (US) 2001-09-12 EP claimed
US-6190731-B1 FORMING A HIGHLY DISPERSED COLLOIDAL SUSPENSION OF PARTICLES, ADDING TO THE SUSPENSION AN ENCAPSULANT MATERIAL TO ENCAPSULATE INDIVIDUAL PARTICLES, AND ISOLATING FROM SAID SUSPENSION INDEPENDENT ENCAPSULATED PARTICLES Tecle, Berhan 2001-02-20 US claimed
US-5922403-A ADDING ENCAPSULANT TO HIGHLY DISPERSED COLLOIDAL SUSPENSION OF SOLID PARTICLES TO ENCAPSULATE INDIVIDUAL PARTICLES; AGGLOMERATING; ISOLATING ENCAPSULATED PARTICLES BY SEPARATION FROM SOLVENT LAYER TECLE, BERHAN 1999-07-13 US claimed
EP-0917501-A1 METHOD FOR ISOLATING ULTRAFINE AND FINE PARTICLES AND RESULTING PARTICLES Tecle, Berhan (US) 1999-05-26 EP claimed
WO-1997033713-A1 METHOD FOR ISOLATING ULTRAFINE AND FINE PARTICLES AND RESULTING PARTICLES TECLE BERHAN (US) 1997-09-18 WO claimed
EP-0396584-B1 ASSAY OF SALICYLATES OR REDUCED PYRIDINE NUCLEOTIDES MICROBIOLOGICAL RES AUTHORITY (GB) 1995-01-25 EP claimed
EP-0396584-A1 ASSAY OF SALICYLATES OR REDUCED PYRIDINE NUCLEOTIDES. HEALTH LAB SERVICE BOARD (GB) 1990-11-14 EP claimed
WO-1989005356-A1 ASSAY OF SALICYLATES OR REDUCED PYRIDINE NUCLEOTIDES THE PUBLIC HEALTH LABORATORY SERVICE BOARD (GB) 1989-06-15 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250178995-A1 COMPOSITIONS AND METHODS FOR THE PRODUCTION OF GLUCARIC ACID G6PD, SOD1, UGDH DYRK1A 2424/4885NPC1 4104/4885RAB9A 3888/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.